Janssen, Vedanta enter license deal for lead microbiome pharmaceutical candidate
The deal, facilitated by the Johnson & Johnson Innovation Center, will see Janssen develop and may commercialize the pharmaceutical candidate in inflammatory bowel disease (IBD). As part of